These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 18290849

  • 21. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
    Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, Lenderink AW.
    Mult Scler; 2004 Feb; 10(1):89-91. PubMed ID: 14760960
    [Abstract] [Full Text] [Related]

  • 22. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [Abstract] [Full Text] [Related]

  • 23. Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis.
    Hoogervorst EL, Kalkers NF, van Winsen LML, Uitdehaag BM, Polman CH.
    Mult Scler; 2001 Oct; 7(5):335-9. PubMed ID: 11724450
    [Abstract] [Full Text] [Related]

  • 24. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double-blind, non-inferiority trial.
    Hervás-García JV, Ramió-Torrentà L, Brieva-Ruiz L, Batllé-Nadal J, Moral E, Blanco Y, Cano-Orgaz A, Presas-Rodríguez S, Torres F, Capellades J, Ramo-Tello C.
    Eur J Neurol; 2019 Mar; 26(3):525-532. PubMed ID: 30351511
    [Abstract] [Full Text] [Related]

  • 25. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
    Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.
    Neurology; 2001 Oct 09; 57(7):1239-47. PubMed ID: 11591843
    [Abstract] [Full Text] [Related]

  • 26. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.
    Nos C, Sastre-Garriga J, Borràs C, Río J, Tintoré M, Montalban X.
    Mult Scler; 2004 Aug 09; 10(4):413-6. PubMed ID: 15327039
    [Abstract] [Full Text] [Related]

  • 27. Impact of Vitamin A Supplementation on Disease Progression in Patients with Multiple Sclerosis.
    Bitarafan S, Saboor-Yaraghi A, Sahraian MA, Nafissi S, Togha M, Beladi Moghadam N, Roostaei T, Siassi F, Eshraghian MR, Ghanaati H, Jafarirad S, Rafiei B, Harirchian MH.
    Arch Iran Med; 2015 Jul 09; 18(7):435-40. PubMed ID: 26161708
    [Abstract] [Full Text] [Related]

  • 28. A study validating changes in the multiple sclerosis functional composite.
    Hoogervorst EL, Kalkers NF, Uitdehaag BM, Polman CH.
    Arch Neurol; 2002 Jan 09; 59(1):113-6. PubMed ID: 11790238
    [Abstract] [Full Text] [Related]

  • 29. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.
    Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass MK, Miller D, Simonian NA.
    Neurology; 2001 May 22; 56(10):1324-30. PubMed ID: 11376182
    [Abstract] [Full Text] [Related]

  • 30. Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life.
    Bethoux F, Miller DM, Kinkel RP.
    Mult Scler; 2001 Apr 22; 7(2):137-42. PubMed ID: 11424634
    [Abstract] [Full Text] [Related]

  • 31. [Change of interleukin-4 and interleukin-12 levels after therapy of multiple sclerosis relapse with methylprednisolone].
    Bartosik-Psujek H, Magryś A, Montewka-Kozioł M, Stelmasiak Z.
    Neurol Neurochir Pol; 2005 Apr 22; 39(3):207-12. PubMed ID: 15981158
    [Abstract] [Full Text] [Related]

  • 32. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.
    Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A.
    Mult Scler; 2004 Feb 22; 10(1):41-6. PubMed ID: 14760951
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis.
    Najmi Varzaneh F, Najmi Varzaneh F, Azimi AR, Rezaei N, Sahraian MA.
    Acta Neurol Belg; 2014 Dec 22; 114(4):273-8. PubMed ID: 24604685
    [Abstract] [Full Text] [Related]

  • 34. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
    Kallweit U, Jelcic I, Braun N, Fischer H, Zörner B, Schreiner B, Sokolov AA, Martin R, Weller M, Linnebank M.
    Clin Neuropharmacol; 2012 Dec 22; 35(2):77-80. PubMed ID: 22318192
    [Abstract] [Full Text] [Related]

  • 35. Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.
    Waldman AT, Chahin S, Lavery AM, Liu G, Banwell BL, Liu GT, Balcer LJ.
    Mult Scler Relat Disord; 2016 Nov 22; 10():73-78. PubMed ID: 27919503
    [Abstract] [Full Text] [Related]

  • 36. A review of interferon use in patients with relapsing remitting multiple sclerosis in the Canterbury region, New Zealand: 2000-2006.
    Byrne S, Mason D.
    N Z Med J; 2012 Feb 24; 125(1350):37-44. PubMed ID: 22382255
    [Abstract] [Full Text] [Related]

  • 37. Relapses in multiple sclerosis: effects of high-dose steroids on cortical excitability.
    Ayache SS, Créange A, Farhat WH, Zouari HG, Mylius V, Ahdab R, Abdellaoui M, Lefaucheur JP.
    Eur J Neurol; 2014 Apr 24; 21(4):630-6. PubMed ID: 24471453
    [Abstract] [Full Text] [Related]

  • 38. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TOWER Trial Group.
    Lancet Neurol; 2014 Mar 24; 13(3):247-56. PubMed ID: 24461574
    [Abstract] [Full Text] [Related]

  • 39. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
    Young PJ, Lederer C, Eder K, Daumer M, Neiss A, Polman C, Kappos L, Sylvia Lawry Centre for Multiple Sclerosis Research.
    Neurology; 2006 Sep 12; 67(5):804-8. PubMed ID: 16966541
    [Abstract] [Full Text] [Related]

  • 40. Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis.
    Oreja-Guevara C, Charil A, Caputo D, Cavarretta R, Sormani MP, Filippi M.
    Arch Neurol; 2006 May 12; 63(5):736-40. PubMed ID: 16682543
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.